Schoenherr advises Sanofi on acquisition of Origimm Biotechnology GmbH

Schoenherr (Schönherr Rechtsanwälte) | View firm profile

Schoenherr advised Sanofi, a global leader in healthcare, on the acquisition of 100 % of the shares in Origimm Biotechnology GmbH, a private Austrian biotechnology company.

The Schoenherr team supported Sanofi in all legal aspects of the transaction, including a full due diligence on the target company and a variety of specific intellectual property-related matters, working closely with the Sanofi inhouse-teams. The share purchase agreement was signed on 30 November 2021, closing is scheduled for 3 December 2021.

Sanofi is a global life sciences company committed to improving access to healthcare and supporting people throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare.

Origimm (‘Origins of Immunity’) is an Austrian biotech company with lead expertise in discovery of vaccine antigens and drug targets for prevention and treatment of diseases and infections associated with skin-colonising microbes.

The Schoenherr team was co-led by Roman Perner (partner) and Michael Marschall (attorney at law), and further consisted of Michael Woller (partner) and Stefanie Aichhorn-Wöss (counsel). The team was supported by Christoph Haid (partner); Alexander Pabst (associate); Teresa Waidmann (counsel); Daniel Komarek (associate); Daniel Neuwirth-Riedl (associate); and Marco Thorbauer (attorney at law).

Squire Patton Boggs (Rüdiger Herrmann; Jochen Eimer; Frankfurt) acted as transaction counsel for the sellers. The founder, seller and CEO Sanja Selak was represented by Binder Grösswang (Thomas Schirmer; Mona Holzgruber).

More from Schoenherr (Schönherr Rechtsanwälte)